What "helps" tumors evade vascular targeting treatment?

Chinese Medical Journal

Volumn 121, Issue 9, 2008, Pages 844-849

  Si, Zhi Chao ^a   Liu, Jie ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Angiogenesis; Resistance; Tumor; Vascular targeting treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR 1; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BREAST CARCINOMA; CANCER STEM CELL; CELL HYPOXIA; CONSENSUS; DRUG TREATMENT FAILURE; ENDOTHELIUM CELL; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; METASTASIS; NONHUMAN; NUTRIENT SUPPLY; OXYGEN SUPPLY; PHENOTYPE; PUBLICATION; REVIEW; STEM CELL MOBILIZATION; TUMOR CELL; TUMOR RECURRENCE; TUMOR VASCULARIZATION; BLOOD VESSEL; CYTOLOGY; DRUG EFFECT; NEOPLASM; STEM CELL; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BLOOD VESSELS; CELL HYPOXIA; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; STEM CELLS;

EID: 51149083070     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200805010-00017     Document Type: Review

References (48)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Marx J. Cancer. Encouraging results for second-generation anti-angiogenesis drugs. Science 2005; 308: 1248-1249.
3. Hu Y, Sun CY, Huang J, Hong L, Zhang L, Chu ZB. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J 2007; 120: 1672-1677.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hansworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastaticcolorectal cancer. N Engl J Med 2004; 350: 2335-2342
5. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
6. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
7. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H, et al, Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006; 10: 413-423.
8. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008 Jan 3, Epub ahead of print.
9. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
10. Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, et al. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol 2006; 94: 242-247.
11. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, et al. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 2006; 98:261-266.
12. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006; 15: 525-532.
13. Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y, Hasan T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 2006; 66: 10953-10958.
14. Hanahan, D. Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364.
15. Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004; 350:2406-2408.
16. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
17. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006; 9: 287-300.
18. Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, et al. Aktl regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 2005, 11: 1188-1196.
19. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002, 8: 27-34.
20. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
21. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159-170.
22. El-Fmir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Regent RH, et al. Tuniour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005, 41: 799-806.
23. Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis-dependent? J Pathol 2004; 202: 5-13.
24. Blagosklomy MV. Anti-angiogenic therapy and tumor progression. Cancer Cell 2004; 5: 13-17.
25. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2: 306-314.
26. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996; 41: 177-185.
27. Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427: 787.
28. Holmgren L, O'Reilly M, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
29. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002; 62: 2162-2168.
30. Goodison S, Kawai K, Hihara J, Jiang P, Yang M, Urquidi V, et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 2003; 9:3808-3814.
31. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-456.
32. Udagawa T, Fernandez A, Achilles EQ Folkman J, D'Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002; 16: 1361-1370.
33. Indraccolo S, Stievano L, Minuzzo S, Tosello, V, Esposito G, Piovan E, et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci U S A 2006; 103:4216-4221.
34. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-699.
35. Jones RJ, Matsui W H, Smith BD. Cancer stem cells: are we missing the target? J Natl Cancer Inst 2004; 96: 583-585.
36. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
37. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506-5511.
38. San L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006; 9: 287-300.
39. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-438.
40. Garmy-Susini B, Varner JA. Circulating endothelial progenitor cells. Br J Cancer 2005; 93: 855-858.
41. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
42. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491-2499.
43. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-435.
44. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of anti-angiogenesis. Cancer Cell 2005; 7: 101-111.
45. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313:1785-1787.
46. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005; 62: 846-853.
47. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 261-262.
48. Baselga J, Tabernero J. Combined anti-angiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet. J Clin Oncol 2007; 25: 4516-4518.